Eight patients had stable disease (SD) for more than 3 months, and one patient with advanced renal cell carcinoma had SD for more than 3.9 years.229 In addition to monotherapy, varlilumab has also been used in combination with anti-PD-L1 antibodies.230 The antitumor effect of this CD27 agonist still needs further, larger-scale investigation.227. Here, CD274 is linked to hereditary clear cell renal cell carcinoma.